Impact of Olmesartan Medoxomil on Amiodarone‐Induced Pulmonary Toxicity in Rats: Focus on Transforming Growth Factor‐ß1
This study was performed to evaluate the effect of olmesartan medoxomil (OM) on lung injury induced in rats by AD which was assessed biochemically (hydroxyproline content, MDA level and SOD activity), histologically (Ashcroft criteria and Masson's trichrome stain) and immunohistochemically (TGF‐β1 expression in lung tissue). The expression levels of TGF‐β1 and type I collagen mRNA were also determined by quantitative real‐time polymerase chain reaction. Forty‐eight adult male rats were randomized into six equal groups: control group, OM control groups, AD group received 40 mg/kg/day, p.o. for 4 weeks to induce pu...
Source: Basic and Clinical Pharmacology and Toxicology - February 5, 2016 Category: Drugs & Pharmacology Authors: Abeer A. I. Sharaf El‐Din, Omaima M. Abd Allah Tags: Original Article Source Type: research
Impact of Olmesartan Medoxomil on Amiodarone‐ Induced Pulmonary Toxicity in Rats: Focus on Transforming Growth Factor‐ßeta‐1
This study was performed to evaluate the effect of olmesartan medoxomil (OM) on lung injury induced in rats by AD which was assessed biochemically (hydroxyproline content, MDA level and SOD activity), histologically (Ashcroft criteria and Masson's trichrome stain) and immunohistochemically (TGF‐β1 expression in lung tissue). The expression levels of TGF‐β1 and type I collagen mRNA were also determined by quantitative real‐time polymerase chain reaction. Forty‐eight adult male rats were randomized into six equal groups; control group, OM control groups, AD group received 40 mg/kg/day, p.o. for four weeks to induce...
Source: Basic and Clinical Pharmacology and Toxicology - January 18, 2016 Category: Drugs & Pharmacology Authors: Abeer A. I. Sharaf El‐Din, Omaima M. Abd Allah Tags: Original Article Source Type: research
The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling
Conclusions:
These data added to our previous results further provide a mechanistic rationale for olmesartan’s antioxidant/anti-inflammatory potential translation, in the long term, toward anti-atherosclerotic/anti-remodeling effects reported by clinical trials. (Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS)
Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS - December 23, 2015 Category: Biomedical Science Authors: Ravarotto, V., Pagnin, E., Maiolino, G., Fragasso, A., Carraro, G., Rossi, B., Calo, L. A. Tags: Original Articles Source Type: research
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
Conclusion
In Korean patients with moderate hypertension not controlled with dual FDC therapy (OM/HCTZ 20/12.5) as first-line therapy, switching to triple FDC therapy (OM/AML/HCTZ 20/5/12.5) was associated with significant BP reductions and greater achievement of BP goals, and was well tolerated (ClinicalTrials.gov Identifier: NCT01838850). (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 21, 2015 Category: Cardiology Source Type: research
Three-way analysis of the UPLC-PDA dataset for the multicomponent quantitation of hydrochlorothiazide and olmesartan medoxomil in tablets by parallel factor analysis and three-way partial least squares.
Abstract
An application of parallel factor analysis (PARAFAC) and three-way partial least squares (3W-PLS1) regression models to ultra-performance liquid chromatography-photodiode array detection (UPLC-PDA) data with co-eluted peaks in the same wavelength and time regions was described for the multicomponent quantitation of hydrochlorothiazide (HCT) and olmesartan medoxomil (OLM) in tablets. Three-way dataset of HCT and OLM in their binary mixtures containing telmisartan (IS) as an internal standard was recorded with a UPLC-PDA instrument. Firstly, the PARAFAC algorithm was applied for the decomposition of...
Source: Talanta - December 16, 2015 Category: Chemistry Authors: Dinç E, Ertekin ZC Tags: Talanta Source Type: research
Molecules, Vol. 20, Pages 21346-21363: Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
During the process development for multigram-scale synthesis of olmesartan medoxomil (OM), two principal regioisomeric process-related impurities were observed along with the final active pharmaceutical ingredient (API). The impurities were identified as N-1- and N-2-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl derivatives of OM. Both compounds, of which N-2 isomer of olmesartan dimedoxomil is a novel impurity of OM, were synthesized and fully characterized by differential scanning calorimetry (DSC), infrared spectroscopy (IR), nuclear magnetic resonance spectroscopy (NMR) and high-resolution mass spectrometry/electrospray ion...
Source: Molecules - December 1, 2015 Category: Chemistry Authors: Iwona DamsAnna OstaszewskaMaria PuchalskaJustyna ChmielPiotr CmochIwona BujakAgata BiałońskaWojciech Szczepek Tags: Article Source Type: research
Synthesis of Olmesartan Medoxomil
Synfacts 2015; 11: 1235-1235DOI: 10.1055/s-0035-1560847© Georg Thieme Verlag Stuttgart · New YorkArticle in Thieme eJournals:Table of contents | Full text (Source: Synfacts)
Source: Synfacts - November 17, 2015 Category: Chemistry Tags: Synthesis of Natural Products and Potential Drugs Source Type: research
Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study.
Abstract
We conducted a retrospective cohort study to evaluate and compare the long-term effects of two single-pill fixed-dose combinations (FDCs), candesartan/amlodipine and olmesartan/azelnidipine, on laboratory parameters in patients in routine clinical practice. We identified an equal number of new users (n = 182) of a candesartan/amlodipine (8/5 mg/day) FDC tablet (CAN/AML users) and a propensity-score matched cohort (n = 182) receiving an olmesartan/azelnidipine (20/16 mg/day) FDC tablet (OLM/AZ users). Generalized estimating equations were used to estimate and compare the effects of the ...
Source: Clinical and Experimental Hypertension - October 9, 2015 Category: Cardiology Authors: Susa N, Nishida Y, Yada Y, Nakayama T, Asai S, Takahashi Y Tags: Clin Exp Hypertens Source Type: research
Immunopathogenesis of olmesartan‐associated enteropathy
ConclusionsOlmesartan‐associated enteropathy shares many features with coeliac disease, including symptoms and immunopathogenic pathways, such as increased numbers of CD8+ cells and corresponding overexpression of IL15 by epithelial cells. Taken together, the treatment of epithelial cells with olmesartan medoxomil induces a response by intestinal epithelial cells that is similar to the innate effects of gluten upon the epithelium of coeliac patients. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - October 1, 2015 Category: Drugs & Pharmacology Authors: E. V. Marietta, A. M. Nadeau, A. K. Cartee, I. Singh, A. Rishi, R. S. Choung, T.‐T. Wu, A. Rubio‐Tapia, J. A. Murray Tags: Original Article Source Type: research
Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: Systematic development, in vitro, ex vivo and in vivo evaluation
Publication date: 30 September 2015 Source:International Journal of Pharmaceutics, Volume 493, Issues 1–2 Author(s): Sarwar Beg, Gajanand Sharma, Kaushik Thanki, Sanyog Jain, O.P. Katare, Bhupinder Singh The current research work explores the potential applications of cationic self-nanoemulsifying oily formulations (CSNEOFs) for enhancing the oral bioavailability of olmesartan medoxomil. Initial preformulation studies, risk assessment and factor screening studies revealed selection of oleic acid, Tween 40 and Transcutol HP as the critical factors. Systematic optimization of SNEOFs was carried out employin...
Source: International Journal of Pharmaceutics - August 15, 2015 Category: Drugs & Pharmacology Source Type: research
2,4-Dimethoxybenzyl Group for the Protection of Tetrazole: An Efficient Synthesis of Olmesartan Medoxomil through C–H Arylation
SynthesisDOI: 10.1055/s-0034-1378848The 2,4-dimethoxybenzyl (DMB) group was found to be effective for protecting tetrazoles. The DMB group is inert to various conditions, including those for ruthenium-catalyzed C–H arylation, but is readily cleaved under mild conditions. The use of a DMB protecting group permitted a synthesis of highly functionalized olmesartan medoxomil in a few steps.[...]© Georg Thieme Verlag Stuttgart · New YorkArticle in Thieme eJournals:Table of contents | Abstract | Full text (Source: Synthesis)
Source: Synthesis - July 10, 2015 Category: Chemistry Authors: Seki, Masahiko Tags: paper Source Type: research
Adding Hydrochlorothiazide to Olmesartan/Amlodipine Increases Efficacy in Patients With Inadequate Blood Pressure Control on Dual‐Combination Therapy
This randomized, parallel‐group study in patients inadequately controlled on olmesartan medoxomil/amlodipine (OLM/AML) 40/10 mg assessed the effects of adding hydrochlorothiazide (HCTZ) 12.5 mg and 25 mg, using seated blood pressure (SeBP) measurements and ambulatory blood pressure (BP) monitoring. Enrolled patients were screened and tapered off of therapy if required. All patients received OLM/AML 40/10 mg and those with mean seated BP (SeBP) ≥140/90 mm Hg after 8 weeks (n=808) were randomized (1:1:1) to continue with OLM/AML 40/10 mg or receive OLM/AML/HCTZ 40/10/12.5 or 40/10/25 mg for a further 8 week...
Source: The Journal of Clinical Hypertension - July 1, 2015 Category: Cardiology Authors: Lars C. Rump, Bettina Ammentorp, Petra Laeis, Jürgen Scholze Tags: Original Paper Source Type: research
Fp076 * effect of olmesartan medoxomil on p63rhogef and rhoa/rho kinase activity in hypertensive patients
(Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Calo', L. A., Ravarotto, V., Pagnin, E., Vertolli, U., Carraro, G., Maiolino, G. Tags: HYPERTENSION. EXPERIMENTAL Source Type: research
A Review of Current Evidence of Olmesartan Medoxomil Mimicking Symptoms of Celiac Disease
Conclusions:
There is growing evidence supporting the association between olmesartan and sprue-like symptoms; however, further research is warranted. These symptoms can be life threatening and clinicians should be aware of the potential association. (Source: Journal of Pharmacy Practice)
Source: Journal of Pharmacy Practice - April 12, 2015 Category: Drugs & Pharmacology Authors: Sanford, M. L., Nagel, A. K. Tags: Review Articles Source Type: research
Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology
Publication date: Available online 20 March 2015 Source:Saudi Pharmaceutical Journal Author(s): Zenab Attari , Amita Bhandari , P.C. Jagadish , Shaila Lewis The purpose of this study was to develop nanosuspension based on combinative technology to enhance the intestinal absorption of Olmesartanmedoxomil(OLM), a potent antihypertensive agent with limited oral bioavailability. Two combinative approaches were employed and then characterized. In vitro intestinal absorption of OLM nanosuspension and plain OLM was studied using non-everted rat intestinal sac model.Optimal OLM nanosuspension was prepared by a combination ...
Source: Saudi Pharmaceutical Journal - March 21, 2015 Category: Drugs & Pharmacology Source Type: research
